Mednet Logo

How would you best manage a medically inoperable oral cavity squamous cell carcinoma that is locally advanced and node-positive with likely extranodal extension?

Consider 6 fractions weekly chemoRT? Add cetuximab to chemoRT? Proton boost? Induction chemo prior to chemoRT? Interstitial H&N brachytherapy boost is not widely available.
7 Answers
Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of Michigan
Answered on

Assuming the patient can receive chemotherapy, the expected DFS from standard concurrent chemo-RT is 50% or less. Options to try and improve the prognosis are 1. Higher RT dose than standard, 2. Altered fractionation alone, 3. Altered fractionation concurrent with chemo, 4. Adding cetuximab to concu...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of Florida
Answered on

Chemo RT with altered fractionation. Induction chemo would be ok but probably doesn’t improve cure rate. Brachytherapy would be off the table because of the extent of disease. Simply not reasonably covered with an implant.

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Norfolk and Norwich University Hospital
Answered on

Given that all the above options have a low chance of cure, supportive care with palliative RT or palliative chemo are also good options and should be discussed with the patient.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · University of Florida
Answered on

Aggressive chemoRT which probably won’t work. That said, hats off to Grant Achatz, U. Chicago, and Alinea. Long odds from my perspective. Kudos! My plan probably would not have worked. 74.4 Gy at 1.2 Gy bid with cisplatin 30 mg/M2 per week.

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · HCA South Atlantic
Answered on

For medically inoperable but surgically resectable patients (T3/T4a), performance status and medical co-morbidities are also an important consideration in my practice while selecting non-surgical treatment. Another important consideration is the sub-site within the oral cavity. In my experience, buc...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Radiation Oncology · HCA South Atlantic
Answered on

It is important to remember that dose/treatment intensification may not be the most optimal/practical approach for patients who are inoperable due to medical co-morbidities.

Join for free or sign in to see the full answer

Mednet Member
Mednet Member
Radiation Oncology · Cancer Care Centers of Brevard
Answered on

Chemo-RT and keep the pd-l1 therapy/keytruda on standby for the inevitable persistent/recurrent disease.

Join for free or sign in to see the full answer